Use of docosahexaenoic acid in treating hypoxic pulmonary hypertension disease drugs
By regulating HIF-2α ubiquitination and degradation through DHA, the problem of specific treatment for hypoxia-induced pulmonary hypertension has been solved, achieving safe, economical, and effective prevention and treatment, and is suitable for prevention and treatment in high-altitude populations.
Patent Information
- Application Number
- CN202610801236.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-06-04
- Publication Date
- 2026-07-17
AI Technical Summary
Existing drugs lack specific treatment for hypoxia-induced pulmonary hypertension, and are expensive with significant side effects. They are not suitable for long-term prevention and intervention in large-scale high-altitude exposure populations, and there is a lack of safe, economical, and effective prevention and treatment strategies.
By using docosahexaenoic acid (DHA) to regulate the ubiquitination and degradation of hypoxia-inducible factor-2α (HIF-2α) protein, abnormal proliferation and migration of pulmonary artery smooth muscle cells are inhibited, thereby improving pulmonary vascular remodeling and cardiomyocyte function through a multi-level synergistic mechanism.
It significantly improves the pathological changes of pulmonary hypertension under hypoxic conditions, enhances aerobic endurance, reduces pulmonary vascular remodeling, and restores cardiopulmonary function. It is suitable for preventive intervention and therapeutic applications for people living, working, training, and traveling at high altitudes.
Smart Images
Figure CN122398772A_ABST